• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

advisory board

  1. Consulting’ for pharma companies: is it worth the time of day?

    As an senior academic +25 years service, I have seen a dive to’ the bottom when’ we are invited to provide consulting services and’ ad board service to the’ pharmaceutical sectors’. They are paying less good rates, flights on cheapest enc class seats, on bugdet airlines for senior PhD or more...
Top Bottom
Back